Hemophilia
We recommend
Smaller Volume and Faster Infusion Rate of aPCC: What Do Current Data Say About This Modification?
Podání infuze s koncentrátem aktivovaného protrombinového komplexu (aPCC) při standardizované rychlosti 2 U/kg/min může být zvláště při potřebě opakovaných aplikací časově náročné. Autoři níže citované čerstvě publikované multicentrické studie se proto zaměřili na bezpečnost a tolerabilitu o 50 % sníženého objemu infuze a její rychlosti zvýšené na 4 a 10 U/kg/min.
Results of Prophylactic Treatment of Severe von Willebrand Disease with Recombinant vWF
Níže citovaná studie fáze III hodnotila účinnost a bezpečnost 12měsíční profylaxe rekombinantním…
Evaluation of Joint Condition in Daily Practice in the Era of New Hemophilia Treatment
With the development of new treatment options for hemophilia, there has also been progress in…
Articles on this topic
Critical Overview of Clinical Studies on EHL FVIII Preparations
An international team of experts recently published a comprehensive work evaluating the…
Rurioctocog Alfa Pegol vs. Non-factor Therapy – Report from Real Clinical Practice
The standard treatment for hemophilia A is the prophylactic administration of coagulation…
Bone density in hemophiliacs − known and less-known risk factors
Osteopenia or osteoporosis are known comorbidities of hemophilia and concern many of these…
Time is Blood! Impact of Diagnostic Delays on Prognosis of Patients with Acquired Hemophilia A
The famous slogan of neurologists in connection with strokes – 'Time is brain!' – can be…
Prophylaxis EHL products FVIII bring improvements in clinical and pharmacokinetic results
A freshly published real-world clinical practice study from Spain highlights the experience of…
Impact of Prophylaxis on Reducing the Risk of Neurological Problems Associated with Bleeding in Hemophilia A
Bleeding can also cause complications in the nervous system of hemophiliacs. The authors of…
Prophylaxis with Rurioctocog Alfa Pegol in Severe Hemophilia A
Rurioctocog alfa pegol represents a modern modality for the treatment of hemophilia from the…
Pharmacokinetic Comparison of Two EHL Products in Hemophilia A
According to a Canadian study published last year, certain pharmacokinetic differences were…
Practical Two-Point Pharmacokinetic Protocol in Hemophilia A
A recently published study confirmed the practicality of a shortened and simple…
Administration of aPCC as a Prevention of Bleeding After Major Cardiac Surgical Procedures
The possibility of actively preventing severe bleeding after a major cardiac surgical…
Subscribe
E-courses on this topic
Most read on this topic
- International Recommendations for COVID-19 Vaccination in People with Bleeding Disorders
- Vascular Disease in the Gradually Aging Population of Hemophiliacs: An Underestimated Problem?
- Administration of aPCC as a Prevention of Bleeding After Major Cardiac Surgical Procedures
- What FVIII Levels Are Ideal for Preventing Bleeding in Hemophilia A?
- COVID-19: Specifics of Care for Individuals with Congenital Bleeding Disorders
- Rurioctocog Alfa Pegol vs. Non-factor Therapy – Report from Real Clinical Practice
Journal on this topic
Related topic
Interesting links